ZEALAND PHARMA A S's ticker is ZEAL and the CUSIP is 98920Y304. A total of 12 filers reported holding ZEALAND PHARMA A S in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,869,000 | -16.6% | 220,523 | -0.4% | 0.00% | – |
| Q1 2022 | $3,442,000 | +6.9% | 221,369 | +46.7% | 0.00% | – |
| Q4 2021 | $3,221,000 | -27.6% | 150,946 | -0.1% | 0.00% | – |
| Q3 2021 | $4,449,000 | +36975.0% | 151,134 | +37873.4% | 0.00% | – |
| Q2 2021 | $12,000 | -45.5% | 398 | -42.7% | 0.00% | – |
| Q1 2021 | $22,000 | +46.7% | 694 | +70.5% | 0.00% | – |
| Q4 2020 | $15,000 | +25.0% | 407 | +30.9% | 0.00% | – |
| Q3 2020 | $12,000 | 0.0% | 311 | -10.6% | 0.00% | – |
| Q2 2020 | $12,000 | -25.0% | 348 | -24.8% | 0.00% | – |
| Q1 2020 | $16,000 | -5.9% | 463 | -10.4% | 0.00% | – |
| Q4 2019 | $17,000 | +70.0% | 517 | +35.7% | 0.00% | – |
| Q3 2019 | $10,000 | +11.1% | 381 | -7.1% | 0.00% | – |
| Q2 2019 | $9,000 | +350.0% | 410 | +177.0% | 0.00% | – |
| Q4 2018 | $2,000 | +100.0% | 148 | +196.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 50 | -40.5% | 0.00% | – |
| Q2 2018 | $1,000 | -92.9% | 84 | -90.4% | 0.00% | – |
| Q1 2018 | $14,000 | – | 875 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FARALLON CAPITAL MANAGEMENT LLC | 510,000 | $18,329,000 | 0.11% |
| AWM Investment Company, Inc. | 19,981 | $718,000 | 0.09% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 5,653 | $203,000 | 0.06% |
| WELLINGTON MANAGEMENT GROUP LLP | 1,099,546 | $39,517,000 | 0.01% |
| ROYCE & ASSOCIATES LP | 10,000 | $359,000 | 0.00% |
| Winslow, Evans & Crocker, Inc. | 235 | $8,000 | 0.00% |
| Renaissance Technologies | 17,205 | $618,000 | 0.00% |
| JANE STREET GROUP, LLC | 35,707 | $1,283,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| Parallel Advisors, LLC | 94 | $3,000 | 0.00% |